The medical device maker's adjusted earnings per share and revenue were more than expected, as sales of its cardiovascular products surged. Boston Scientific gave a mixed updated full-year forecast.
The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...